Female Sexual Dysfunction - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 60 pages report, published by Global Markets Direct

Keywords : Female Sexual Dysfunction Therapeutic Products under Development, Key Players in Female Sexual Dysfunction Therapeutics, Female Sexual Dysfunction Pipeline Overview, Female Sexual Dysfunction Pipeline, Female Sexual Dysfunction Pipeline Assessment

Report ThumbnailSeptember-2013
Female Sexual Dysfunction - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Female Sexual Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Female Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction. Female Sexual Dysfunction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Female Sexual Dysfunction.
- A review of the Female Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Female Sexual Dysfunction pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Female Sexual Dysfunction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Female Sexual Dysfunction pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Female Sexual Dysfunction, H2 2013 8
  • Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Early Clinical Stage Products, H2 2013 13
  • Discovery and Pre-Clinical Stage Products, H2 2013 14
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Female Sexual Dysfunction, H2 2013 8
  • Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
  • Products under Development by Companies, H2 2013 15
  • Bayer AG, H2 2013 16
  • Palatin Technologies, Inc., H2 2013 17
  • M et P Pharma AG, H2 2013 18
  • ANI Pharmaceuticals, Inc., H2 2013 19
  • Medisyn Technologies, Inc., H2 2013 20
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Female Sexual Dysfunction Therapeutics - Drug Profile Updates 41
  • Female Sexual Dysfunction Therapeutics - Discontinued Products 49
  • Female Sexual Dysfunction Therapeutics - Dormant Products 50
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Female Sexual Dysfunction Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Female Sexual Dysfunction 8
  • Female Sexual Dysfunction Therapeutics under Development by Companies 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Early Clinical Stage Products 13
  • Comparative Analysis 13
  • Discovery and Pre-Clinical Stage Products 14
  • Comparative Analysis 14
  • Female Sexual Dysfunction Therapeutics - Products under Development by Companies 15
  • Companies Involved in Female Sexual Dysfunction Therapeutics Development 16
  • Bayer AG 16
  • Palatin Technologies, Inc. 17
  • M et P Pharma AG 18
  • ANI Pharmaceuticals, Inc. 19
  • Medisyn Technologies, Inc. 20
  • Female Sexual Dysfunction - Therapeutics Assessment 21
  • Assessment by Monotherapy Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • testosterone - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • PL-6983 - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • testosterone propionate - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • bremelanotide - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • MC4R Agonist - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • prasterone - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • TBS-2 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • SIP-104 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • S1B-307 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • S1B-3006 - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • Next Generation Melanocortin Receptor Specific Peptide - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Female Sexual Dysfunction Therapeutics - Drug Profile Updates 41
  • Female Sexual Dysfunction Therapeutics - Discontinued Products 49
  • Female Sexual Dysfunction Therapeutics - Dormant Products 50
  • Female Sexual Dysfunction - Product Development Milestones 51
  • Featured News & Press Releases 51
  • Jun 03, 2013: Trimel Receives Decision In Connection With Tefina Arbitration 51
  • Mar 01, 2013: Palatin Technologies Presents Positive Data For Bremelanotide In Female Sexual Dysfunction 51
  • Nov 08, 2012: Palatin Technologies Reports Positive Results For Phase IIB Bremelanotide Female Sexual Dysfunction Trial 53
  • Oct 15, 2012: Trimel To Enroll 240 Patients In Phase II Ambulatory Trial Of Tefina 54
  • Sep 10, 2012: Palatin Technologies Announces Last Patient Completed Treatment In Phase IIB Bremelanotide Female Sexual Dysfunction Trial 55
  • Aug 16, 2012: Apricus Biosciences Announces Podium Presentation Of Femprox Phase III Clinical Data At 2012 World Meeting On Sexual Medicine 55
  • Jun 18, 2012: Trimel Hosts Investigator Meeting To Review Phase II Trial Of Tefina 56
  • Jun 15, 2012: Trimel Pharma Receives Approval To Conduct Tefina Clinical Study In Canada 57
  • Jun 11, 2012: BioSante Pharma Announces New LibiGel Phase III Efficacy Trials 57
  • May 21, 2012: Apricus Bio Announces Regulatory Meeting With FDA For Femprox For Treatment Of Female Sexual Arousal Disorder 58
  • Appendix 59
  • Methodology 59
  • Coverage 59
  • Secondary Research 59
  • Primary Research 59
  • Expert Panel Validation 59
  • Contact Us 60
  • Disclaimer 60

Please select a license type

Share

Related Products

Global Markets DirectFemale Sexual Dysfunction - Pipeline Review, H2 2013Product ThumbnailFemale Sexual Dysfunction - Pipeline Review, H2 2013, Industry ReportProduct #: 113306
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved